Lupin Gives Direction On Pegfilgrastim And Ranibizumab
Neulasta Biosimilar Previously Slated For FY2021
Executive Summary
Indian major Lupin is continuing to further efforts on its three main growth drivers: biosimilars, inhalation products and long-acting injectables, management told the virtual J.P. Morgan Healthcare Conference in San Francisco.
You may also be interested in...
Lupin Gets Another First With Fostair
Lupin has claimed a first with a UK approval for a rival to Fostair. The Indian company has told Generics Bulletin that it is planning to roll out the Luforbec branded generic later this year.
Lupin Expects Respiratory Ramp Up From Fiscal '22
After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.
Perrigo’s ProAir Rival ‘Unlikely To Be Back In 2021’ Following Recall
Perrigo has moved to allay more serious concerns around its generic ProAir inhaler device, but concedes that it is highly unlikely the lucrative respiratory product will return to the market this year.